MAPP..$16.49 There are too many risks with this FDA PDUFA play on March 26th. The stock is extremely overvalued at a market cap of 500m. The company does not have a SPA for their Phase III clinical studies. There has been one study conducted instead of the usual two. They stated they did in the past but the FDA cannot find it. There has not been an Advisory Panel convened in place of that. This is an inhaled product so it did not go through the scrutiny that inhaled therapies like Adasuve (ALXA) have gone through. There are a lot of fishy circumstances with this company starting with a late filing then the missing SPA. Good luck to those in it.
News 
Market Data 
Discover 
